Rational choice of cholinesterase inhibitor for the treatment of Alzheimers disease in Canada: a comparative economic analysis

摘要

BackgroundCholinesterase inhibitors, such as galantamine, donepezil and rivastigmine are approved for symptomatic treatment of Alzheimer's Disease (AD) in Canada. In making choices amongst these drugs, one should consider their clinical merits and their economic implications.